Markets:

Overview

News

Currencies

International

Treasuries

Invesco Nasdaq Biotechnology ETF (NQ:IBBQ)

35.20 -0.85 (-2.36%)

Official Closing Price Updated: 4:15 PM EDT, Sep 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Invesco Nasdaq Biotechnology ETF

Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ ↗

September 02, 2026

Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns.

Via The Motley Fool

Topics ETFs

Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket? ↗

August 22, 2026

VanEck's concentrated 25-stock approach offers higher individual company exposure, while Invesco's broader 251-position portfolio delivered 47.4% returns over the past year.

Via The Motley Fool

Topics ETFs

IBBQ vs. PBE: Which Biotech ETF Is the Better Buy? ↗

August 21, 2026

PBE concentrates on 31 companies and offers a higher dividend yield, while IBBQ spreads risk across 251 holdings at a fraction of the cost.

Via The Motley Fool

Topics ETFs

uniQure Stock Tumbled 56% Today: What’s The FDA Angle? ↗

November 03, 2025

Via Stocktwits

Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? ↗

August 19, 2026

One offers concentrated exposure to 29 pharma giants with lower volatility, while the other provides broader diversification across 251 biotech companies at a cheaper cost.

Via The Motley Fool

Topics ETFs

Which Is the Better Invesco Healthcare ETF: Equal-Weight RSPH or Biotech-Focused IBBQ? ↗

August 12, 2026

RSPH levels the playing field across 60 established healthcare names while IBBQ bets on more than 250 biotech companies at a lower cost.

Via The Motley Fool

Topics ETFs

XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy? ↗

August 01, 2026

IBBQ posted the stronger return over the past year, but has also experienced much higher historical volatility than XLV.

Via The Motley Fool

Topics ETFs Intellectual Property

Better Healthcare Sector ETF: Vanguard's Broad VHT vs. Invesco's Biotechnology-Focused IBBQ ↗

July 26, 2026

Vanguard's broad sector approach costs half as much and yields twice the dividend, while Invesco's biotech focus delivered stronger 1-year returns but with steeper downside risk.

Via The Motley Fool

Topics ETFs

Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026? ↗

July 22, 2026

One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains.

Via The Motley Fool

Topics ETFs

IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy? ↗

July 18, 2026

IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.

Via The Motley Fool

Topics ETFs

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? ↗

July 11, 2026

IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH? ↗

July 08, 2026

IBBQ offers lower costs and broader diversification, while XPH delivered stronger 1-year returns with less volatility.

Via The Motley Fool

Topics ETFs

Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? ↗

June 04, 2026

Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.

Via The Motley Fool

Topics ETFs

Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug ↗

November 24, 2025

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said.

Via Stocktwits

Applied Therapeutics To Lay Off Nearly Half Its Staff, Board Explores M&A Options ↗

November 20, 2025

The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said.

Via Stocktwits

Topics Workforce

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally ↗

October 17, 2025

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.

Via Stocktwits

Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’ ↗

June 12, 2025

The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease.

Via Stocktwits

These 4 ETFs Provide Smart Exposure To Intuitive Machines, The New Space Economy ↗

March 21, 2025

Intutive Machines specializes in lunar missions and sophisticated space technologies. These ETFs are worth looking at.

Via Benzinga

Topics ETFs

5 Undervalued ETFs To Ride On Powell's Market Optimism ↗

March 20, 2025

Here are five ETFs from different zones of the market that are currently undervalued and could generate solid returns in a rising stock market.

Via Talk Markets

Topics ETFs

Tempus AI Stock Eyes Best Rally In 5 Months Amid Pelosi-Linked Hype, But Retail’s Turning Doubtful Now ↗

January 23, 2025

A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.

Via Stocktwits

Topics Artificial Intelligence

FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch ↗

August 19, 2024

The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak.

Via Benzinga

Topics ETFs

Time For Gilead Sciences-Heavy ETFs? ↗

September 12, 2023

Gilead Sciences has underperformed the broader market this year by a hefty margin.

Via Talk Markets

Biotech ETFs Pop On M&A Resurgence ↗

May 10, 2023

The biopharma industry has seen a recent upswing in mergers and acquisitions (M&A).

Via Talk Markets

Should You Buy Biotech ETFs Now? ↗

June 16, 2021

Instead of trying to pick winners in this volatile space, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and...

Via Talk Markets

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.